Latest News

Guselkumab, Golimumab Combination Therapy Leads to High Rates of Clinical Response for Ulcerative Colitis
Guselkumab, Golimumab Combination Therapy Leads to High Rates of Clinical Response for Ulcerative Colitis

February 3rd 2023

The rate of adverse events was lower in the combination group than it was in patients in the guselkumab or golimumab monotherapy groups at week 50.

Microneedling, 5-Fluorouracil More Efficient Than Tacrolimus Monotherapy for Vitiligo
Microneedling, 5-Fluorouracil More Efficient Than Tacrolimus Monotherapy for Vitiligo

February 3rd 2023

Multidisciplinary Lifestyle Program Decreased Disease Activity in Patients With Rheumatoid Arthritis
Multidisciplinary Lifestyle Program Decreased Disease Activity in Patients With Rheumatoid Arthritis

February 3rd 2023

Raising Awareness of Complications Associated with Sickle Cell Trait
Raising Awareness of Complications Associated with Sickle Cell Trait

February 2nd 2023

A Bevacizumab-First Treatment Approach for DME May Be Cost-Effective
A Bevacizumab-First Treatment Approach for DME May Be Cost-Effective

February 2nd 2023

Conference Coverage

View All
Laura Wingate: Improving All Aspects of Care for IBD Patients
Laura Wingate: Improving All Aspects of Care for IBD Patients

February 1st 2023

Kirsten Johansen, MD: Improving the Quality of Life for CKD Patients With Anemia
Kirsten Johansen, MD: Improving the Quality of Life for CKD Patients With Anemia

January 31st 2023

Jennifer Crosbie, PhD: A Video Game Platform for Improving Executive Function
Jennifer Crosbie, PhD: A Video Game Platform for Improving Executive Function

January 30th 2023

Katie Falloon, MD: Studying IBD-Associated Peripheral Arthritis
Katie Falloon, MD: Studying IBD-Associated Peripheral Arthritis

January 24th 2023

Video Series
View All
Video Interviews
View All
Podcasts
View All

All News

© 2023 MJH Life Sciences

All rights reserved.